{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:24:56Z","timestamp":1749853496764},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.dld.2005.04.026","type":"journal-article","created":{"date-parts":[[2005,7,18]],"date-time":"2005-07-18T14:47:53Z","timestamp":1121698073000},"page":"741-750","source":"Crossref","is-referenced-by-count":20,"title":["Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease"],"prefix":"10.1016","volume":"37","author":[{"given":"F.","family":"Pace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Annese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Casalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Nardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Bianchi","family":"Porro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2005.04.026_bib1","unstructured":"Peterson WL. Improving the management of GERD. Evidence-based therapeutic strategies. AGA Consensus Opinion in Gastroenterology 2002, available at www.aga.com."},{"key":"10.1016\/j.dld.2005.04.026_bib2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/BF01071906","article-title":"Symptomatic gastroesophageal reflux: incidence and precipitating factors","volume":"21","author":"Nebel","year":"1976","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.dld.2005.04.026_bib3","unstructured":"The Gallup Organization. A Gallup Organization National Survey: Heartburn across America. Princeton: 1988."},{"key":"10.1016\/j.dld.2005.04.026_bib4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1046\/j.1365-2036.2000.00884.x","article-title":"The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms","volume":"14","author":"Kennedy","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00464-002-9229-4","article-title":"The impact of gastroesophageal reflux disease on quality of life","volume":"17","author":"Kamolz","year":"2003","journal-title":"Surg Endosc"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2005.04.026_bib6","first-page":"35","article-title":"Quality of life assessment in gastro-oesophageal reflux disease","volume":"53","author":"Irvine","year":"2004","journal-title":"Gut"},{"issue":"Suppl. 221","key":"10.1016\/j.dld.2005.04.026_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/00365529609095544","article-title":"Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease","volume":"31","author":"Dimenas","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-199802000-00004","article-title":"Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole","volume":"10","author":"Carlsson","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2005.04.026_bib9","first-page":"37","article-title":"Natural course of gastroesophageal reflux disease: 17\u201322 year follow-up of 60 patients","volume":"92","author":"Isolauri","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib10","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptoms relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2005.04.026_bib11","doi-asserted-by":"crossref","unstructured":"Van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease [Cochrane review]. Cochrane Database Syst Rev 2000;2:CD002095.","DOI":"10.1002\/14651858.CD002095"},{"key":"10.1016\/j.dld.2005.04.026_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1018822532736","article-title":"Rabeprazole in treatment of acid peptic disease: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD)","volume":"43","author":"Cloud","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2005.04.026_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1572-0241.2000.02233.x","article-title":"Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial","volume":"95","author":"Farley","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","article-title":"Double-blind placebo-controlled comparison of rabeprazole 20mg vs. omeprazole 20mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease","volume":"13","author":"Dekkers","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/003655200453566","article-title":"Rabeprazole, 20mg once daily or 10mg twice daily, is equivalent to omeprazole, 20mg once daily, in the healing of erosive gastro-oesophageal reflux disease","volume":"35","author":"Delchier","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2036.2002.01207.x","article-title":"A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib17","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1111\/j.1572-0241.2000.03179.x","article-title":"Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rabeprazole Study Group","volume":"95","author":"Caos","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1053\/j.gastro.2004.03.005","article-title":"Are claims of equivalency in digestive diseases trials supported by the evidence?","volume":"126","author":"Tinmouth","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2005.04.026_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: the importance of rigorous methods","volume":"313","author":"Jones","year":"1996","journal-title":"Br Med J"},{"key":"10.1016\/j.dld.2005.04.026_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0197-2456(82)90024-1","article-title":"Proving the null hypothesis in clinical trials","volume":"3","author":"Blackwelder","year":"1982","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.dld.2005.04.026_bib21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1046\/j.1365-2036.2003.01496.x","article-title":"Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors","volume":"17","author":"Pantoflickova","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","article-title":"Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive esophagitis","volume":"16","author":"Robinson","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib23","unstructured":"Fennerty MB. When should endoscopy be done in the patient with reflux? Medscape Gastroenterol 2003;5. Available at http:\/\/www.medscape.com\/viewarticle\/450231."},{"key":"10.1016\/j.dld.2005.04.026_bib24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1572-0241.1999.1123_a.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"94","author":"DeVault","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S1590-8658(02)80259-6","article-title":"On demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease","volume":"34","author":"Pace","year":"2002","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.dld.2005.04.026_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/gut.33.1.118","article-title":"Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease","volume":"33","author":"Bell","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.dld.2005.04.026_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.1995.tb00777.x","article-title":"The relationship between the control of pH and healing and symptoms relief in gastro-oesophageal reflux disease","volume":"9","author":"Hunt","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00042737-199809000-00005","article-title":"Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis","volume":"10","author":"Newton","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2005.04.026_bib29","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1111\/j.1572-0241.2001.05263.x","article-title":"Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.026_bib30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","article-title":"A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole vs omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects","volume":"12","author":"Williams","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1365-2036.2002.01292.x","article-title":"Effects of rabeprazole, 20mg, or esomeprazole, 20mg, on 24-h intragastric pH and serum gastrin in healthy subjects","volume":"16","author":"Warrington","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.026_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00042737-200012080-00008","article-title":"Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease","volume":"12","author":"Birbara","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2005.04.026_bib33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1005548318996","article-title":"Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. A double-blind, multicenter, European trial","volume":"45","author":"Thjodleifsson","year":"2000","journal-title":"Dig Dis Sci"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086580500232X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086580500232X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T08:08:42Z","timestamp":1586333322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086580500232X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S159086580500232X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2005.04.026","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}